RHOGTPase-Related Gene Signature Predicts Prognosis, Immunotherapy Response, and Chemotherapy Sensitivity in Colon Cancer.

Clicks: 134
ID: 282899
2025
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #47 of 51 articles by views in Applied biochemistry and biotechnology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Rho GTPases are known to promote colon cancer cell invasion and metastasis by modulating cell motility and adhesion. However, the clinical implications of Rho GTPase-related genes in prognosis and treatment response for colon cancer remain underexplored. We identified Rho GTPase-related prognostic genes using univariate Cox regression and applied Least Absolute Shrinkage and Selection Operator (LASSO) regression to refine these genes and develop a prognostic model. The Rho GTPase-related gene signature was analyzed for associations with clinical outcomes, immune status, immunotherapy, and chemotherapy response in colon cancer patients. A Rho GTPase-related 12-gene signature was established to predict prognosis across training and validation cohorts. Both univariate and multivariate analyses confirmed the Rho GTPase risk score as an independent prognostic factor. The model's area under the curve (AUC) and decision curve analysis (DCA) outperformed traditional TNM staging and several existing models. Immune cell analysis showed high Rho GTPase risk scores correlated with increased macrophage/monocyte and cancer-associated fibroblast infiltration. Tumor Immune Dysfunction and Exclusion (TIDE) analysis revealed an association between high Rho GTPase risk scores and immune dysfunction, suggesting potential resistance to immune checkpoint inhibitors in high-risk patients. Additionally, differential sensitivity to 59 chemotherapeutics was observed: high-risk patients showed greater sensitivity to CCT007093, CGP.082996, and AS601245, while low-risk patients were more sensitive to BMS.708163, NSC.87877, and Cisplatin, informing potential treatment choices. The Rho GTPase-related 12-gene signature offers a valuable tool for predicting prognosis and therapeutic response in colon cancer, supporting personalized treatment strategies and improved patient outcomes.
Reference Key
zhang2025rhogtpaserelated Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Zhang, Bixiong; Xu, Lingli; Ji, Yuran; Li, Jiezhuang; Liu, Liehui; Li, Liangfang; Zhuo, Zewei; Zheng, Zhongwen
Journal Applied biochemistry and biotechnology
Year 2025
DOI
10.1007/s12010-025-05262-9
URL
Keywords
Chemotherapy prognosis colon cancer rho gtpase immune therapy

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.